Patent Application: Cancer Treatment Compositions and Methods

ChangeBridge: Patent Apps - Peptides (C07K)

Published July 16th, 2025

Detected March 26th, 2026

Summary

The USPTO has published a new patent application (US20260085120A1) for compositions and methods related to cancer treatment. The application describes binding agents, carrier proteins, and therapeutic agents, particularly for cancers expressing PD-LI or PD-L2, and lyophilized compositions.

View original document View source feed page

What changed

This document is a publication of a patent application filed with the USPTO, specifically application US20260085120A1, titled 'Carrier-PD-L1 Binding Agent Compositions for Treating Cancers.' The application details compositions involving binding agents and carrier proteins, optionally with therapeutic agents, and methods for their use in treating cancers. It also describes lyophilized compositions and methods for treating cancers by administering a nanoparticle composition and a PD-1 immunotherapy to patients whose cancer expresses PD-LI or PD-L2.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on entities. However, it signals potential future intellectual property and market exclusivity for novel cancer treatments. Companies in the pharmaceutical and biotechnology sectors should monitor the progress of this application and similar filings for insights into emerging therapeutic technologies and potential licensing or competitive landscapes.

Source document (simplified)

← USPTO Patent Applications

Carrier-PD-L1 Binding Agent Compositions for Treating Cancers

Application US20260085120A1 Kind: A1 Mar 26, 2026

Inventors

Svetomir N. Markovic, Wendy K. Nevala

Abstract

Described herein are compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic. Still also described are methods for treating and/or increasing the therapeutic effectiveness of an immunotherapy of a patient suffering from a cancer which expresses PD-LI or PD-L2 by administering to the patient a nanoparticle composition and a PD-I immunotherapy.